AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Founded in 2020, Neomorph has been garnering interest from big pharma for its discovery platform. Last year, it signed separate multi-billion dollar partnerships with big-wigs Biogen BIIB and Novo ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...